Takeda Pharmaceutical (NYSE:TAK) Stock Rating Upgraded by Sanford C. Bernstein

Takeda Pharmaceutical (NYSE:TAK) was upgraded by Sanford C. Bernstein from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday, MarketBeat reports.

A number of other equities research analysts have also weighed in on TAK. Wall Street Zen lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 21st. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Finally, Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They issued an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $18.47 on Wednesday. The firm has a market cap of $58.76 billion, a PE ratio of 76.94 and a beta of -0.01. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average is $18.20 and its two-hundred day moving average is $15.97.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The firm had revenue of $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, research analysts expect that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TAK. Arrowstreet Capital Limited Partnership grew its position in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the last quarter. UBS Group AG grew its position in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd grew its position in shares of Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after buying an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after buying an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its position in shares of Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after buying an additional 880,289 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.